Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:60060
Name non-Hodgkin lymphoma
Definition A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
NRAS mutant Trametinib non-Hodgkin lymphoma resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00513474 Phase I Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant Completed USA 0
NCT00576654 Phase I Irinotecan Veliparib Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT00577278 Phase II Ibritumomab tiuxetan Methotrexate + Sirolimus + Tacrolimus Rituximab Fludarabine + Melphalan A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan Completed USA 0
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed USA 0
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated USA 0
NCT00740805 Phase I Aldoxorubicin + Cyclophosphamide + Veliparib Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT00854152 Phase I Apitolisib A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma Completed USA | GBR 0
NCT00857389 Phase II Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed USA 0
NCT01032148 Phase I Panobinostat Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma Terminated USA 0
NCT01058239 Phase II Bortezomib + Rituximab Bortezomib Plus Rituximab for EBV+ PTLD Completed USA 0
NCT01076543 Phase Ib/II Lenalidomide + Temsirolimus Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Completed USA 0
NCT01162551 Phase II Methotrexate + Sirolimus Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma Completed USA 0
NCT01187810 Phase I Fenretinide Cytarabine Methotrexate Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL Terminated USA 0
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed USA 1
NCT01306643 Phase Ib/II Idelalisib Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma Completed USA 0
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed USA | ITA | FRA | AUS 1
NCT01321346 Phase I Cytarabine Panobinostat A Study Of Panobinostat In Children With Refractory Hematologic Malignancies Completed USA 0
NCT01324180 Phase I Metformin Dexamethasone + Doxorubicin + Pegaspargase + Vincristine Sulfate Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) Completed USA 0
NCT01333046 Phase I MultiTAA-specific T cells Azacitidine + MultiTAA-specific T cells Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (TACTAL) Active, not recruiting USA 0
NCT01353625 Phase I CC-115 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Completed USA | FRA | ESP | DEU 0
NCT01408043 Phase I Etoposide + Filgrastim + Plerixafor Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma Terminated USA 0
NCT01421524 Phase I CC-122 Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Completed USA | ITA | FRA | ESP | BEL 0
NCT01581541 Phase I PU-H71 PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin s Lymphoma That Have Not Responded to Standard Treatment Terminated USA 0
NCT01592370 Phase I Nivolumab Ipilimumab Lirilumab Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma Active, not recruiting USA | ITA | FRA | BEL 2
NCT01609816 Phase Ib/II Dasatinib Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant Terminated USA 0
NCT01614197 Phase I Etoposide Cyclophosphamide Prednisone Cytarabine Temsirolimus Methotrexate A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma Completed USA | CAN | AUS 0
NCT01621477 Phase II Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Terminated USA 0
NCT01634217 Phase I Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation Completed USA 0
NCT01660451 Phase II Copanlisib Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 15
NCT01686165 Phase II Belinostat Rituximab Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Completed USA 0
NCT01701986 Phase Ib/II Tacrolimus Rituximab Filgrastim Mycophenolate mofetil anti-thymocyte globulin Busulfan + Clofarabine + Gemcitabine Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas Active, not recruiting USA 0
NCT01719250 Phase I Buparlisib Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed USA 0
NCT01732913 Phase III Idelalisib Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated USA | ITA | GBR | FRA | ESP | DEU | AUS 12
NCT01732926 Phase III Idelalisib Bendamustine + Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 7
NCT01742988 Phase Ib/II Bendamustine + CUDC-907 + Rituximab CUDC-907 + Rituximab CUDC-907 CUDC-907 + Venetoclax Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma Completed USA 0
NCT01745354 Phase I SD-101 Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) Terminated USA 0
NCT01746849 Phase II Leuprolide Cyclophosphamide Thiotepa Palifermin Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting USA 0
NCT01811368 Phase II anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT01822509 Phase I Ipilimumab + Nivolumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Completed USA 0
NCT01871675 Phase I Rituximab Duvelisib Bendamustine Phase Ib Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies Completed USA 0
NCT01882803 Phase II Duvelisib A Phase 2 Study of IPI-145 in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO) Completed USA | ITA | GBR | FRA | ESP | CAN | BEL 5
NCT01905813 Phase I Dezapelisib + Itacitinib Dezapelisib Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting USA 0
NCT01949883 Phase I CPI-0610 A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Completed 0
NCT01953692 Phase I Pembrolizumab A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) Completed 0
NCT01983969 Phase Ib/II Rituximab Dexamethasone Busulfan + Melphalan Azacitidine + Gemcitabine + Vorinostat Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Completed USA 0
NCT01992653 Phase I Cyclophosphamide + Doxorubicin + Prednisone Rituximab Polatuzumab vedotin-piiq Obinutuzumab A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma Completed USA | FRA 0
NCT01994382 Phase I Cerdulatinib Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma Completed USA 0
NCT02000934 Phase I Mivavotinib A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies Completed USA | ITA | GBR | ESP 0
NCT02018861 Phase I Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies Completed USA 0
NCT02028455 Phase Ib/II Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia Active, not recruiting USA 0
NCT02043587 Phase II Rituximab Pegaspargase Methotrexate Cytarabine Leucovorin Cyclophosphamide Dasatinib Daunorubicin Vincristine Sulfate Etoposide Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Terminated USA 0
NCT02055820 Phase I Venetoclax Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Obinutuzumab A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma Completed USA | ITA | FRA | ESP | CAN | AUT | AUS 3
NCT02061761 Phase Ib/II Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies Completed USA | CAN 0
NCT02082977 Phase I GSK126 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma Terminated USA | GBR | FRA 0
NCT02091063 Phase Ib/II Ricolinostat ACY-1215 for Relapsed/Refractory Lymphoid Malignancies Completed USA 0
NCT02098109 Phase II Plerixafor Filgrastim Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Completed USA 0
NCT02104427 Phase II Burixafor Filgrastim PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients Completed USA 0
NCT02110563 Phase I DCR-MYC Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma Terminated USA 0
NCT02130869 Phase I Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas Completed USA 0
NCT02142530 Phase I Belinostat Carfilzomib Carfilzomib Plus Belinostat in Relapsed/Refractory NHL Completed USA 0
NCT02155582 Phase I Copanlisib Copanlisib Pharmacodynamic Study Completed GBR | FRA | BEL 0
NCT02180711 Phase I Acalabrutinib An Open-label, Phase 1b Study of ACP 196 in Subjects With Follicular Lymphoma Active, not recruiting USA | ITA | CAN 0
NCT02200380 Phase II Plerixafor CDX-301 A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Terminated USA 0
NCT02204982 Phase III Duvelisib Rituximab Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R) Terminated ITA | FRA | AUS 1
NCT02281279 Phase Ib/II Lenalidomide + Rituximab + Romidepsin Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma Withdrawn 0
NCT02287311 Phase I LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) Recruiting USA 0
NCT02304458 Phase Ib/II Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Completed USA | CAN 0
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Completed USA | GBR 0
NCT02329847 Phase Ib/II Ibrutinib + Nivolumab Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies Completed USA | ESP | AUS 3
NCT02343666 Phase I Filgrastim Carmustine Plerixafor O6-benzylguanine HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection Withdrawn USA 0
NCT02348216 Phase Ib/II axicabtagene ciloleucel A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) Completed USA | FRA | DEU | CAN 2
NCT02361346 Phase Ib/II MT-3724 Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001) Terminated USA | ESP | CAN 7
NCT02367040 Phase III Rituximab Copanlisib Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT | AUS 29
NCT02367196 Phase I CC-90002 + Rituximab CC-90002 A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers Completed USA | ESP 0
NCT02408042 Phase Ib/II Rituximab Carboplatin + Etoposide + Ifosfamide Pembrolizumab Brentuximab vedotin Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) Withdrawn USA 0
NCT02487459 Phase I Rivogenlecleucel Rimiducid Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies Withdrawn USA 0
NCT02529813 Phase I Cyclophosphamide + Fludarabine + Tisagenlecleucel CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Completed USA 0
NCT02541604 Phase I Atezolizumab A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN 4
NCT02543879 Phase I FT-1101 Azacitidine + FT-1101 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Completed USA 0
NCT02576496 Phase I Tinostamustine Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Active, not recruiting USA | ITA | FRA | ESP | DEU 2
NCT02594384 Phase I LAM-002A A Phase I Dose Escalation Study A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL) Completed USA 0
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Active, not recruiting USA 0
NCT02611323 Phase Ib/II Polatuzumab vedotin-piiq + Rituximab + Venetoclax Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Completed USA | ITA | AUS 0
NCT02613598 Phase I Bortezomib + Ruxolitinib Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma Completed USA 0
NCT02635672 Phase I VIP152 Phase I Dose Escalation Study for BAY 1251152 in Patients With Advanced Cancer Active, not recruiting USA | ESP 1
NCT02651662 Phase I Cemiplimab Cemiplimab + Odronextamab Study of REGN2810 and REGN1979 in Patients With Lymphoma Recruiting USA | ESP | DEU 0
NCT02662296 Phase II Idelalisib Ibrutinib Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant Withdrawn USA 0
NCT02663297 Phase I ATLCAR.CD30 cells Administration of T Lymphocytes for Prevention of Relapse of Lymphomas Active, not recruiting USA 0
NCT02690545 Phase Ib/II ATLCAR.CD30 cells Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL Recruiting USA 0
NCT02701673 Phase Ib/II Azacitidine Pyridoxine Gemcitabine Belinostat Busulfan Melphalan Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma Withdrawn 0
NCT02702492 Phase I KPT-9274 KPT-9274 + Niacin PAK4 and NAMPT in Patients With Solid MAlignancies or NHL (PANAMA) (PANAMA) Terminated USA | CAN 0
NCT02703272 Phase III Ibrutinib Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine Sulfate A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma Terminated USA | GBR | FRA | ESP | DEU | CAN | BEL 13
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy in CBT Recruiting USA 0
NCT02732275 Phase I DS-3201b DS-3201b in Participants With Lymphomas Active, not recruiting USA 1
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Completed USA | FRA | CAN 1
NCT02790515 Phase II Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting USA 0
NCT02797470 Phase Ib/II Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Active, not recruiting USA 0
NCT02867618 Phase Ib/II Carfilzomib + Umbralisib Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma Terminated USA 0
NCT02875067 Phase Ib/II Lenalidomide + Pembrolizumab Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma Terminated USA 0
NCT02875223 Phase I CC-90011 A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas Active, not recruiting ITA | GBR | FRA | ESP 1
NCT02890758 Phase I ALT-803 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Completed USA 0
NCT02917083 Phase I ATLCAR.CD30 cells + Cyclophosphamide + Fludarabine CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (RELY-30) Recruiting USA 0
NCT02925234 Phase II Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab The Drug Rediscovery Protocol (DRUP Trial) (DRUP) Recruiting 1
NCT02953509 Phase Ib/II Hu5F9-G4 + Rituximab Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Active, not recruiting USA | GBR | AUS 0
NCT02954406 Phase I Lenalidomide + Mivavotinib Ibrutinib + Mivavotinib Gemcitabine + Mivavotinib Bendamustine + Mivavotinib + Rituximab Bendamustine + Mivavotinib A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma Terminated USA | CAN 0
NCT02960646 Phase I Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed USA 0
NCT02961816 Phase II Pyridoxine Busulfan + Gemcitabine + Melphalan + Panobinostat Dexamethasone + Filgrastim + Palifermin + Rituximab Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma Withdrawn 0
NCT02973113 Phase I EB-VST cells + Nivolumab Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE) Completed USA 0
NCT02978235 Phase Ib/II TAS4464 A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma Terminated USA 0
NCT03015896 Phase Ib/II Lenalidomide + Nivolumab Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Active, not recruiting USA 0
NCT03019666 Phase I Allogeneic NAM NK cells Cyclophosphamide + Fludarabine Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL Completed USA 0
NCT03035331 Phase Ib/II Pembrolizumab Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT03036904 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine Sulfate Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R) Completed USA 0
NCT03056339 Phase Ib/II Cyclophosphamide + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies Completed USA 0
NCT03081910 Phase I CD5 CAR T cells Cyclophosphamide + Fludarabine Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) Recruiting USA 0
NCT03082209 Phase I ABBV-621 A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies Completed USA | ESP 2
NCT03105336 Phase II axicabtagene ciloleucel A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5) Active, not recruiting USA | FRA 0
NCT03119467 Phase I RP4010 Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Terminated USA | AUS 0
NCT03133221 Phase II Idelalisib 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Active, not recruiting USA 0
NCT03147885 Phase Ib/II Selinexor Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT03153462 Expanded access axicabtagene ciloleucel + Cyclophosphamide + Fludarabine Axicabtagene Ciloleucel Expanded Access Study Approved for marketing USA 0
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting USA | CAN | AUS 1
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Active, not recruiting USA 0
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Completed USA | GBR | CAN 4
NCT03206671 Phase III Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Vincristine Sulfate Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (B-NHL 2013) Recruiting DEU | AUT 6
NCT03207256 Phase II Ublituximab + Umbralisib Umbralisib Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials Terminated USA 0
NCT03210662 Phase II Pembrolizumab Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL) Recruiting USA 0
NCT03210714 Phase II Erdafitinib Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting FRA | ESP | AUS 6
NCT03213652 Phase II Ensartinib Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Recruiting USA | AUS 1
NCT03213665 Phase II Tazemetostat Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213678 Phase II LY3023414 Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213691 Phase II Selumetinib Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213704 Phase II Larotrectinib Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03218683 Phase I AZD5991 Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. Terminated USA 0
NCT03220035 Phase II Vemurafenib Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03233204 Phase II Olaparib Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03258567 Phase II Nivolumab Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas Recruiting USA 0
NCT03259503 Phase Ib/II Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas Active, not recruiting USA 0
NCT03263637 Phase I AZD4573 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Completed GBR | DEU 1
NCT03283137 Phase I Pembrolizumab + Umbralisib Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL Active, not recruiting USA 0
NCT03297424 Phase Ib/II PLX2853 A Study of PLX2853 in Advanced Malignancies. Completed USA 0
NCT03297606 Phase II Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) Recruiting CAN 0
NCT03352765 Phase I Bendamustine + Melphalan + Rituximab A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients Active, not recruiting USA 0
NCT03357627 Phase I Mivavotinib + Venetoclax A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma Completed USA | DEU | CAN 0
NCT03357757 Phase II Avelumab + Valproic acid Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) Active, not recruiting CAN 0
NCT03366272 Phase II Gemcitabine + Nivolumab + Oxaliplatin + Rituximab Gemcitabine + Oxaliplatin + Rituximab Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients (NIVEAU) Active, not recruiting FRA | DEU | BEL | AUT 4
NCT03379493 Phase I Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma Terminated USA 0
NCT03424603 Phase I STRO-001 Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Active, not recruiting USA 0
NCT03432741 Phase I Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Suspended USA 0
NCT03467373 Phase I Tocilizumab Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Glofitamab-gxbm Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Prednisone + Rituximab + Vincristine Sulfate A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 1
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Active, not recruiting USA 0
NCT03484702 Phase II Lisocabtagene maraleucel Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD) Completed ITA | GBR | FRA | ESP | DEU | BEL | AUT 4
NCT03505762 Phase II Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment Active, not recruiting USA 0
NCT03526250 Phase II Palbociclib Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03527147 Phase I Acalabrutinib + Danvatirsen Acalabrutinib + Ceralasertib Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) Completed USA | GBR 0
NCT03531736 Phase I Rituximab Cyclophosphamide + Fludarabine T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia Active, not recruiting USA 0
NCT03537482 Phase I APG-2575 APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies Recruiting USA | AUS 0
NCT03556228 Phase I VMD-928 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Recruiting USA 1
NCT03571568 Phase Ib/II BI-1206 + Rituximab A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Recruiting USA | ESP | DEU 3
NCT03579888 Phase I CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells + Cyclophosphamide + Fludarabine CD19-Specific T Cells Post AlloSCT Terminated USA 0
NCT03583424 Phase Ib/II Carmustine + Cytarabine + Etoposide + Melphalan + Venetoclax Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Unknown status USA 0
NCT03598608 Phase Ib/II MK-4280 + Pembrolizumab Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) Recruiting USA | ITA | DEU | CAN | AUS 1
NCT03677141 Phase Ib/II Tocilizumab Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Prednisone Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Prednisone + Vincristine Sulfate A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Completed USA | FRA | ESP | AUT 2
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03707093 Phase I ADG106 Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma Completed USA 0
NCT03713580 Phase I Carmustine + Cytarabine + Etoposide + Melphalan + Venetoclax Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT03740529 Phase Ib/II Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Active, not recruiting USA | ITA | GBR | FRA | AUS 5
NCT03744676 Phase II Lisocabtagene maraleucel A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) Completed USA 0
NCT03755154 Phase I VOB560 Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia Active, not recruiting GBR | FRA | ESP | AUS 0
NCT03772288 Phase I Mivavotinib + NKTR-214 A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) Withdrawn USA | CAN 0
NCT03786926 Phase Ib/II HMPL-689 Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas Active, not recruiting USA | ITA | FRA | ESP 2
NCT03789097 Phase Ib/II CDX-301 + Pembrolizumab + Poly ICLC Vaccination With Flt3L, Radiation, and Poly-ICLC Recruiting USA 0
NCT03797261 Phase I AMG 176 + Venetoclax A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies Terminated USA | DEU | AUS 0
NCT03809624 Phase II INBRX-105 INBRX-105 + Pembrolizumab Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) Recruiting USA 0
NCT03829254 Phase Ib/II NUC-7738 NUC-7738 + Pembrolizumab A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma Recruiting GBR 0
NCT03884998 Phase I Copanlisib + Nivolumab Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma Active, not recruiting USA 0
NCT03885947 Phase I Cyclophosphamide + Fludarabine + Thiotepa VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies Completed USA 0
NCT03893682 Phase I CG-806 A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas Active, not recruiting USA 0
NCT03900598 Phase I JNJ-67856633 A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | AUS 5
NCT03921879 Phase I OT-82 Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma Unknown status USA 0
NCT03925935 Phase I AB-205 Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation Completed USA 0
NCT03930953 Phase I CC-99282 CC-99282 + Rituximab A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL) Recruiting USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT 7
NCT03938987 Phase Ib/II Cyclophosphamide + Fludarabine Anti-CD19 CAR-T cells Anti-CD19, Dual Co-stimulatory (4-1BB, CD3zeta) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002) Recruiting CAN 0
NCT03983668 Phase Ib/II Pembrolizumab + Vidutolimod CMP-001 for Relapsed and Refractory Lymphoma Recruiting USA 0
NCT03997968 Phase Ib/II CYT01B A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Active, not recruiting USA 0
NCT04029038 Phase Ib/II CD19/CD22 CAR T cells Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Withdrawn USA 0
NCT04035434 Phase Ib/II CTX110 A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies Recruiting USA | FRA | ESP | DEU | CAN | AUS 0
NCT04038359 Phase II Duvelisib A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO) Completed USA | ITA | GBR | DEU 4
NCT04045028 Phase I Tiragolumab Daratumumab + Tiragolumab Rituximab + Tiragolumab A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Terminated USA 1
NCT04068597 Phase Ib/II CCS1477 Study to Evaluate CCS1477 in Haematological Malignancies Recruiting USA | GBR | FRA | ESP 1
NCT04074330 Phase Ib/II Rituximab + Subasumstat A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN 2
NCT04089527 Phase I FT-1101 Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma Completed FRA | ESP 0
NCT04136756 Phase I NKTR-255 Daratumumab + NKTR-255 NKTR-255 in Relapsed/Refractory Multiple Myeloma and Non Hodgkin Lymphoma and Combined With Daratumumab for Multiple Myeloma Completed USA 0
NCT04161118 Phase II huCART19 TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (TIGER-CTL019) Terminated DEU 0
NCT04205409 Phase II Nivolumab Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies Active, not recruiting USA 0
NCT04220008 Phase II Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Rituximab + Tacrolimus + Vorinostat Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Tacrolimus + Vorinostat Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma Withdrawn 0
NCT04233697 Phase I Copanlisib + Romidepsin Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma Withdrawn 0
NCT04240704 Phase I JBH492 Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) Active, not recruiting ESP | DEU 5
NCT04277637 Phase I BGB-11417 + Zanubrutinib BGB-11417 Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies Recruiting USA | ITA | GBR | ESP | DEU | AUS 1
NCT04323657 Phase Ib/II Cyclophosphamide + Fludarabine TC-110 T-cells TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Completed USA 0
NCT04328844 Phase I IOA-244 A Study to Assess a PI3Kdelta Inhibitor (IOA-244) in Patients With Metastatic Cancers Active, not recruiting ITA | GBR 0
NCT04331119 Phase II Duvelisib Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas Recruiting USA 0
NCT04390737 Phase I HH2853 A Phase I Study to Evaluate the Safety and Clinical Activity of HH2853. Recruiting USA 1
NCT04401020 Phase I SAR442257 First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL Active, not recruiting USA | ESP 3
NCT04500587 Phase I ZN-d5 Phase 1 First in Human Study of ZN-d5 as a Single Agent Recruiting ESP | AUS 5
NCT04543305 Phase I PRT1419 A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies Completed USA 0
NCT04545762 Phase I Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Recruiting USA 0
NCT04663347 Phase Ib/II Epcoritamab-bysp Cisplatin + Cytarabine + Dexamethasone + Epcoritamab-bysp + Rituximab Epcoritamab-bysp + Gemcitabine + Oxaliplatin Epcoritamab-bysp + Lenalidomide + Rituximab Bendamustine + Epcoritamab-bysp + Rituximab Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2) Recruiting USA | ITA | GBR | FRA | ESP | BEL | AUS 6
NCT04673617 Phase Ib/II AB-101 + Bendamustine + Rituximab AB-101 + Rituximab AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT04684108 Phase I SG301 SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies Withdrawn AUS 0
NCT04684563 Phase I HuCART19-IL18 huCART19-IL18 in CD19+ Cancers Recruiting USA 0
NCT04702425 Phase I MIK665 + VOB560 VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) Active, not recruiting USA | ITA | ESP | BEL 5
NCT04703686 Phase II Glofitamab-gxbm + Obinutuzumab Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy Active, not recruiting FRA 0
NCT04718675 Phase I KB-0742 A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma Recruiting USA | GBR | ESP 0
NCT04725331 Phase Ib/II BT-001 BT-001 + Pembrolizumab A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors Recruiting FRA | BEL 0
NCT04730349 Phase Ib/II Nivolumab + NKTR-214 A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (PIVOT IO 020) Terminated USA | ITA | FRA | ESP | DEU | AUS 0
NCT04739293 Phase I Narazaciclib Study of ON 123300 in Patients With Advanced Cancer Recruiting USA 0
NCT04756726 Phase Ib/II CFT7455 CFT7455 + Dexamethasone Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma Recruiting USA 0
NCT04771572 Phase I LP-118 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. Recruiting USA 0
NCT04806035 Phase I TG-1801 + Ublituximab TG-1801 Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia Active, not recruiting USA 0
NCT04827862 Phase II Pembrolizumab RADVAX for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy Recruiting USA 0
NCT04842877 Phase II DS-3201b Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma Active, not recruiting FRA | BEL 0
NCT04851119 Phase Ib/II BC2059 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Recruiting USA 0
NCT04853329 Phase Ib/II CPO107 Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma Suspended USA 0
NCT04860466 Phase I CC-96673 A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma Active, not recruiting USA | FRA | ESP | CAN 0
NCT04872166 Phase I BTX-A51 A Study of BTX-A51 in People With Advanced Solid Tumor or Non-Hodgkin Lymphoma Recruiting USA 0
NCT04876092 Phase I Ibrutinib + JNJ-67856633 A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in B-cell NHL and CLL Active, not recruiting FRA 3
NCT04902443 Phase I Nivolumab + Pomalidomide Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV Recruiting USA 0
NCT04903197 Phase I Lenalidomide + VAY736 VAY736 Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma Recruiting USA | ITA | ESP | DEU | AUS 4
NCT04920383 Phase I ALPN-202 + unspecified PD-1 antibody ALPN-202 With PD-1 Inhibition in Advanced Malignancies (NEON-2) Terminated USA 0
NCT04970901 Phase I Loncastuximab tesirine-lpyl + Umbralisib Lenalidomide + Loncastuximab tesirine-lpyl Loncastuximab tesirine-lpyl + Polatuzumab vedotin-piiq Gemcitabine + Loncastuximab tesirine-lpyl A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS 7) Recruiting USA | ITA | GBR | ESP | BEL 1
NCT04986865 Phase I ATG-101 A Study of Evaluating the Safety and Efficacy of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (PROBE) Recruiting USA | AUS 0
NCT05003141 Phase I PSB202 PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies Unknown status USA | AUS 1
NCT05005299 Phase I Cyclophosphamide + Fludarabine + Venetoclax Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (VICTORY) Recruiting AUS 0
NCT05005442 Phase II MK-7684A A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 10
NCT05020678 Phase I Cyclophosphamide + Fludarabine NKX019 NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Recruiting USA | AUS 0
NCT05025800 Phase Ib/II Evorpacept + Lenalidomide + Rituximab ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT05038150 Phase I SGN1 Study of SGN1 in Patients With Advanced Solid Tumor Recruiting USA 1
NCT05040932 Phase I YH004 Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy Completed AUS 0
NCT05044039 Phase I Duvelisib Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy Recruiting USA 0
NCT05053659 Phase I Loncastuximab tesirine-lpyl + Venetoclax Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma Recruiting USA 0
NCT05103345 Phase I SGN1 Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor Recruiting 2
NCT05134740 Phase I MultiTAA-specific T cells (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). Recruiting USA 0
NCT05144334 Phase I BTX-1188 A Study of BTX-1188 in Subjects With Advanced Malignancies Terminated USA 0
NCT05144347 Phase I XL114 Study of XL114 in Subjects With Non-Hodgkin's Lymphoma Terminated USA 0
NCT05169515 Phase I Glofitamab-gxbm + Iberdomide CC-99282 + Glofitamab-gxbm CC-99282 + Mosunetuzumab-axgb Iberdomide + Mosunetuzumab-axgb A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma Recruiting USA | ITA | GBR | ESP 1
NCT05169658 Phase II Mosunetuzumab-axgb + Obinutuzumab + Polatuzumab vedotin-piiq Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT05171647 Phase III Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Tocilizumab Gemcitabine + Oxaliplatin + Rituximab A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO) Recruiting USA | CAN 12
NCT05181540 Phase III AB-205 A Phase 3 Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (E-CELERATE) Terminated USA 0
NCT05191225 FDA approved Rituximab Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study Unknown status ESP 0
NCT05202782 Phase II Zanubrutinib Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma Recruiting USA 0
NCT05205161 Phase Ib/II AZD0466 A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma Terminated USA | ITA | FRA | ESP | AUS 2
NCT05253495 Phase II Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Rituximab + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Vincristine Sulfate Cytarabine + Etoposide + Polatuzumab vedotin-piiq + Rituximab Cytarabine + Etoposide + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Cytarabine + Methotrexate + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Rituximab + Vinblastine Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (RADICAL) Recruiting USA 0
NCT05255601 Phase Ib/II Nivolumab + Relatlimab A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069) Recruiting USA | ITA | GBR | FRA | ESP | DEU | AUS 1
NCT05272384 Phase I Decitabine and Cedazuridine + Nivolumab Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma Recruiting USA 0
NCT05275504 Phase I TT-01488 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies Recruiting USA 0
NCT05279300 Phase I CS5001 A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas Recruiting USA | AUS 1
NCT05293912 Phase I SG2501 SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma. Recruiting USA 0
NCT05312801 Phase I LMY-920 Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma Recruiting USA 0
NCT05336409 Phase I CNTY-101 A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (ELiPSE-1) Recruiting USA 0
NCT05346809 Phase II Isatuximab Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma Recruiting USA 0
NCT05348889 Phase Ib/II 1A46 First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies Recruiting USA 0
NCT05365659 Phase I IKS03 IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Recruiting USA | CAN | AUS 0
NCT05389423 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Pomalidomide + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Pomalidomide + Prednisone + Rituximab + Vincristine Sulfate Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas Recruiting USA 0
NCT05397496 Phase I PIT565 Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies Recruiting USA | ITA | FRA | ESP | BEL 3
NCT05400109 Phase I Cyclophosphamide + Fludarabine UF-KURE19 Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas Recruiting USA 0
NCT05400122 Phase I Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Suspended USA 0
NCT05415098 Phase I APG-5918 Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05424822 Phase I JNJ-80948543 A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Recruiting USA | FRA | AUS 3
NCT05453396 Phase II Loncastuximab tesirine-lpyl Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Recruiting USA 0
NCT05476770 Phase I Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Tagraxofusp-erzs + Vincristine Sulfate Azacitidine + Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Fludarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Recruiting USA | AUS 0
NCT05515406 Phase I ONO-7018 A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL Recruiting USA 0
NCT05533775 Phase Ib/II Glofitamab-gxbm Carboplatin + Etoposide + Glofitamab-gxbm + Ifosfamide + Rituximab Tocilizumab Obinutuzumab A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX GLO) Recruiting USA | ITA | FRA | ESP | DEU | AUS 2
NCT05537766 Phase II Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25) Recruiting USA | ITA | FRA | ESP | DEU | AUT 2
NCT05588440 Phase Ib/II Cyclophosphamide + Fludarabine ONCT-808 A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies Recruiting USA 0
NCT05607420 Phase Ib/II Alemtuzumab UCART20X22 Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NatHaLi-01) Recruiting USA | FRA | ESP 0
NCT05653271 Phase I ACE1831 + Cyclophosphamide + Fludarabine + Obinutuzumab ACE1831 + Cyclophosphamide + Fludarabine ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies Recruiting USA 1
NCT05665062 Phase I Cyclophosphamide + Fludarabine STK-009 + SYNCAR-001 Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies Recruiting USA 0
NCT05665725 Phase I Siltuximab Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma Recruiting USA 0
NCT05678998 Phase I WTX-330 WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma Recruiting USA 0
NCT05681195 Phase II Pemetrexed Disodium + Zanubrutinib Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas Recruiting USA 0
NCT05685173 Phase I Odronextamab + REGN5837 A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas (ATHENA-1) Recruiting USA | GBR 0
NCT05721222 Phase Ib/II PRO1160 PRO1160 for Advance Solid and Liquid Tumors (PRO1160-001) Recruiting USA 1
NCT05737628 Phase I BYON4228 + Rituximab First-in-human Dose Escalation and Expansion Study With the SIRPalpha-directed Monoclonal Antibody BYON4228 Recruiting ITA | GBR | ESP 1
NCT05753501 Phase I ABBV-101 Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies Recruiting USA 2
NCT05755087 Phase I BC2059 Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma Recruiting USA 0
NCT05779930 Phase I Anti-CD19 CAR-T cells Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL Not yet recruiting USA 0
NCT05784441 Phase I JNJ-90009530 A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Recruiting USA | AUS 0
NCT05798897 Phase I MT-601 Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO) Recruiting USA 0
NCT05801913 Phase I CMV-CD19 CAR T-cells + Multi-antigen CMV-modified vaccinia Ankara vaccine Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT05824585 Phase I DZD8586 DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Not yet recruiting AUS 0
NCT05826535 Phase Ib/II IMPT-314 Study of IMPT-314 in R/R Aggressive B-cell Recruiting USA 0
NCT05878184 Phase I Cyclophosphamide + Fludarabine SC291 Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) Recruiting USA | AUS 0
NCT05892718 Phase I HCB101 A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPa-CD47 Pathway, in Solid or Hematological Tumors Recruiting USA 1
NCT05950165 Phase Ib/II CHO-H01 A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma Recruiting USA 1
NCT05950334 Phase I Bendamustine + FT522 + Rituximab Cyclophosphamide + Fludarabine + FT522 + Rituximab FT522 + Rituximab FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) Recruiting USA 0
NCT05963217 Phase I Cyclophosphamide + Fludarabine TBI-2001 Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL Recruiting CAN 0
NCT05989204 Phase I HuCART19-IL18 TmCD19-IL18 in CD19+ Cancers Recruiting USA 0
NCT06045910 Phase Ib/II ALETA-001 A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies Recruiting GBR 0
NCT06098651 Phase I DCR-STAT3 A Study of DCR-STAT3 in Adults With Solid Tumors Recruiting USA 0
NCT06119685 Phase Ib/II IDP-023 Cyclophosphamide + Fludarabine Daratumumab + IDP-023 Aldesleukin + IDP-023 IDP-023 + Rituximab IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers Recruiting USA 0
NCT06132503 Phase I LP-284 A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors Recruiting USA 0
NCT06173518 Phase I Obecabtagene autoleucel A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) Recruiting GBR 0
NCT06176690 Phase I C7R.CD30.CAR-EBVS T-cells Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas Not yet recruiting USA 0
NCT06188208 Phase I Pembrolizumab + VVD-130850 VVD-130850 A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors Recruiting USA 0
NCT06191887 Phase I Bendamustine BAFFR-CAR T cells Cyclophosphamide + Fludarabine B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Not yet recruiting USA 0
NCT06209619 Phase I CC-99282 + Rituximab CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma Recruiting USA 0
NCT06227026 Phase I Anti-CD19 CAR-T cells Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies (PRODIGY) Recruiting USA 0
NCT06230224 Phase III Carboplatin + Etoposide + Ifosfamide Carboplatin + Etoposide + Ifosfamide + Rituximab Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cisplatin + Cytarabine + Dexamethasone Cisplatin + Dexamethasone + Gemcitabine Odronextamab Cisplatin + Cytarabine + Dexamethasone + Rituximab A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4) Recruiting ITA | ESP | AUS 2
NCT06242834 Phase II Pembrolizumab + Tazemetostat Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Not yet recruiting USA 0
NCT06256484 Phase I ATA3219 A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Recruiting USA 0